Nature Cell Biology: Novel Atherosclerotic Coronary Endothelial Subtype— Cloud-Clone Advances Cardiovasc Transl Research

Single-cell transcriptomics identifies disease-driving endothelial population and validates OGN as a non-invasive circulating biomarker

HUSTON, TX, UNITED STATES, September 10, 2026 /EINPresswire.com/ -- Coronary atherosclerosis represents the pathological root of life-threatening cardiovascular events, yet major gaps persist between pre-clinical animal findings and human vascular pathology. Limited access to graded human coronary tissue samples and the shortage of accessible blood-based screening biomarkers have long hindered translational cardiovascular research. A recent high-impact study published in Nature Cell Biology addresses both challenges by generating staged human coronary single-cell atlases, uncovering a pathogenic endothelial subset, and verifying osteoglycin (OGN) as a promising serum biomarker. Cloud-Clone’s ELISA assay enabled high-throughput protein quantification across clinical serum cohorts to support this end-to-end translational investigation.

Figure 1 Researchers from Fuwai Hospital, Chinese Academy of Medical Sciences published a study in Nature Cell Biology titled “Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression”
Coronary atherosclerosis is a chronic vascular inflammatory disorder driven by multi-cellular interactions and progressive pathological shifts, rather than simple lipid deposition. Vascular endothelial dysfunction acts as the primary trigger across lesion evolution, ranging from early fatty streaks to advanced vulnerable plaques with thin fibrous caps.
Mechanistic studies of atherosclerosis heavily rely on genetically-modified mouse models such as ApoE-/-、Ldlr-/-. Despite valuable contributions to the field, notable inter-species differences exist in vascular anatomy, cellular phenotypes and lipid metabolism. Observations obtained from murine experiments cannot be fully recapitulated within human atherosclerotic tissues. Scarce availability of well-graded human coronary specimens has delayed comprehensive profiling of human vascular cell pathological states.

Figure 2 Fifty-six human coronary artery segments across three distinct atherosclerotic stages were collected for pathological grading and single-cell RNA sequencing (scRNA-seq). (Image credit: Nature Cell Biology)
Current clinical coronary assessment modalities also carry practical limitations. Coronary CTA and angiography directly visualise vascular stenosis but involve radiation exposure and substantial costs, making them unsuitable for large-scale population screening. Simple, widely-available circulating biomarkers capable of non-invasively reflecting total coronary atherosclerotic burden remain an unmet clinical need. Validated serum biomarkers would deliver enormous value for early-stage risk warning and longitudinal monitoring among high-risk populations.
Against these dual bottlenecks, researchers from the State Key Laboratory of Cardiovascular Disease carried out this comprehensive project. The team collected human coronary tissues representing successive pathological stages, deployed single-cell RNA sequencing to decode cellular heterogeneity, mapped key transcriptional regulatory circuits and cell-to-cell communication networks. Complementary clinical serum cohort analysis further screened and validated secreted protein candidates for non-invasive disease evaluation, forming a complete research workflow linking fundamental cellular mechanisms to clinical translation.
Published July 2026 in Nature Cell Biology, the peer-reviewed article titled Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression characterises cell-level alterations during human coronary atherosclerotic advancement.
For this study, 56 human coronary artery specimens were acquired from 19 heart-transplant donors and pathologically categorised into normal, early-stage atherosclerosis and advanced-stage atherosclerosis groups. After sample dissociation, library construction and single-cell sequencing, 27 941 high-quality cells were captured. Nine major cell classes and further 37 vascular and immune cell sub-populations were identified, covering principal plaque-microenvironment constituents including endothelial cells, vascular smooth-muscle cells, fibroblasts, macrophages, T-lymphocytes, B-cells and mast cells.
A standout finding is the identification of a previously unrecognised endothelial sub-population: EC5 SLCO4A1+. This subset displays transcriptional signatures reminiscent of endothelial progenitor cells and exhibits progressive expansion as lesions advance from early to late atherosclerosis. EC5 SLCO4A1+ cells show down-regulated canonical endothelial-barrier genes, enhanced migratory and angiogenic capacity, and compromised vascular barrier integrity. These properties facilitate lipid infiltration and immune-cell recruitment into the intima, marking EC5 SLCO4A1+ as a central cellular driver of human coronary plaque progression.
Investigators next explored molecular triggers converting quiescent endothelial cells into pathogenic EC5 SLCO4A1+. Through transcription-factor prediction, multi-omics screening, CUT&Tag sequencing and primary endothelial functional assays, PRDM15 was pinpointed as the master regulator. CUT&Tag evidence confirmed that PRDM15 directly binds genomic loci to activate SLCO4A1 and other EC5-signature genes, inducing pathological reprogramming in mature endothelial cells.
In-vivo validation was performed using endothelial-specific Prdm15 overexpression and knockout mouse models on the ApoE-/- background:
Endothelial-specific Prdm15 overexpression led to enlarged aortic and coronary plaques, expanded necrotic cores, abundant macrophage infiltration and reduced plaque stability.
Endothelial-specific Prdm15 deletion markedly mitigated atherosclerotic lesions, shrank plaque volume, thickened fibrous caps, improved plaque stability and diminished numbers of EC5-like pathogenic endothelial cells.
Combined in-vitro and in-vivo data establish PRDM15 as a pivotal transcriptional mediator of endothelial progenitor-like pathological reprogramming and a potential therapeutic target for coronary artery disease.
Cell-communication analysis of single-cell datasets characterised signalling crosstalk within plaque microenvironments. EC5 SLCO4A1+ cells secrete high levels of chemokine CXCL9, while pro-inflammatory MP2 act macrophages within plaques express abundant CCL3. The pair forms a bidirectional pro-inflammatory signalling loop: EC5 SLCO4A1+ recruits pro-inflammatory macrophages into lesions, and recruited macrophages in turn release inflammatory mediators that further push endothelial cells toward pathological phenotypes. This self-reinforcing cycle amplifies local chronic inflammation and accelerates plaque deterioration, explaining how endothelial reprogramming reshapes immune microenvironments to worsen atherosclerosis.
From ligand-receptor profiling outputs, 25 secreted protein candidates displaying stage-dependent expression shifts were short-listed. To assess their biomarker potential, a clinical cohort containing 148 patients receiving coronary CTA scans was enrolled. Peripheral serum samples were collected for protein quantification and correlated against clinical coronary-artery-calcification score (CACS).
Clinical cohort validation demonstrated that circulating osteoglycin (OGN) serum concentrations correlate positively with CACS, a well-established readout for total coronary atherosclerotic burden. This finding indicates peripheral OGN levels can indirectly reflect atherosclerotic severity. Subject to further large-cohort verification, OGN may evolve into a convenient serum-based assay for high-risk population screening, disease-severity assessment and longitudinal surveillance, offering an alternative to costly, radiation-dependent coronary CTA examinations.
High-throughput protein measurement across hundreds of clinical serum specimens constituted a critical experimental step within this translational work. ELISA was selected for OGN quantification owing to its independence from large-scale capital equipment, established workflows, flexible throughput and cost-effectiveness for large human-sample cohorts. As a secreted matrix protein, OGN can be measured in serum, plasma, cell-culture supernatants and tissue homogenates. Cloud-Clone provides a full portfolio of reagents for OGN detection suited to atherosclerotic clinical-sample validation, animal-model studies and in-vitro mechanistic assays. The referenced assay used in this publication is Cloud-Clone OGN (Osteoglycin) ELISA Kit, Cat. No. USEC688Hu.
This landmark study opens multiple promising research avenues for basic and translational cardiovascular science:
1.Endothelial plasticity and pathological vascular reprogramming: The discovery of EC5 SLCO4A1+ revises understanding of human coronary endothelial dysfunction. Researchers may further probe upstream signalling cascades and epigenetic regulation governing the PRDM15-SLCO4A1 axis in endothelial injury and vascular remodelling.
2.Plaque-microenvironment crosstalk and inflammatory mechanisms: The CXCL9-CCL3 bidirectional pro-inflammatory circuit between EC5 cells and pro-inflammatory macrophages supports investigations into chronic plaque inflammation. It also enables screening of bioactive compounds capable of interrupting this inflammatory loop for anti-atherosclerotic drug development.
3.Translational development of circulating cardiovascular biomarkers: Expanded clinical cohorts can explore associations between OGN and major adverse cardiovascular events alongside comorbidities including diabetes, hyperlipidaemia and chronic kidney disease. Multi-marker diagnostic panels can also be constructed to boost predictive performance.
4.Identification and validation of novel therapeutic targets: Given PRDM15’s confirmed regulatory role over plaque progression, intervention studies targeting PRDM15 may be pursued to evaluate plaque-stabilising effects for coronary-disease therapeutic development.
5.Multi-omics integrative analysis: The publicly-available human coronary single-cell dataset from this project enables mining for additional candidate genes and secreted proteins to uncover further vascular-disease targets and biomarkers.
News Closing
Leveraging precious graded human coronary specimens and single-cell transcriptomic profiling, this Nature Cell Biology work defines EC5 SLCO4A1+ as a pathogenic endothelial subset driving human coronary atherosclerosis. It delineates PRDM15-governed endothelial progenitor-like reprogramming, maps pro-inflammatory interplays between endothelial and macrophage populations, and validates circulating OGN as a candidate non-invasive biomarker for atherosclerotic burden. The research completes a full translational chain spanning basic discovery, mechanistic verification and clinical biomarker evaluation.
For cardiovascular investigators, the PRDM15/SLCO4A1 axis and CXCL9-CCL3 signalling circuit supply fresh directions for atherosclerosis mechanistic research and therapeutic-target exploration. Cloud-Clone’s OGN ELISA kit supports scalable protein quantification across clinical and animal biospecimens, facilitating biomarker-oriented cohort studies and helping generate more high-impact cardiovascular translational outputs.
Reference Yao, F., Li, F., Gai, S. et al. Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression. Nat Cell Biol (2026). https://doi.org/10.1038/s41556-026-02022-7

SuKi Duan
CLOUD-CLONE CORP.WUHAN
email us here
Visit us on social media:
LinkedIn
Instagram
TikTok
X